Korean J Anesthesiol.  2001 Jul;41(1):47-51. 10.4097/kjae.2001.41.1.47.

Differential Analgesic and Adverse Effects of 0.125% Bupivacaine vs. Ropivacaine Coadministered Epidurally with Morphine

Affiliations
  • 1Department of Anesthesiology, College of Medicine, Pocheon Jungmun University, Songnam, Korea.

Abstract

BACKGROUND: This study aimed to compare analgesic efficacy and occurance of motor block and other side effects of a 48 hr postoperative continuous epidural infusion of 0.125% bupivacaine or ropivacaine with morphine.
METHODS
Forty patients undergoing a Cesarean section were allocated randomly into two groups. Both groups received an epidural injection of 2.0% lidocaine 18 20 ml and 0.5% bupivacaine 2 5 ml with fentanyl 50microgram 20 minutes before surgical incision and received 2 mg of epidural morphine by bolus 40 minutes after surgical incision. For post-operative pain control, a continuous epidural infusion was started using a two day infusor containing 6 mg of morphine in 100 ml of 0.125% bupivacaine (Group 1, n = 20) or 100 ml of 0.125% ropivacaine (Group 2, n = 20). Visual analog scale (VAS) for pain during rest and movement, sensory change and motor blockade were assessed for 48 hrs. after surgery.
RESULTS
There were no significant differences in VAS for pain during rest and movement. The incidences of side effect were similar in both groups.
CONCLUSIONS
Using 0.125% bupivacaine with morphine via the epidural route provided similar pain relief and side effects as 0.125% ropivacaine with morphine.

Keyword

Analgesia: pain; postoperative; Anesthetic techniques: epidural; Anesthetics, local: bupivacaine; ropivacaine

MeSH Terms

Bupivacaine*
Cesarean Section
Female
Fentanyl
Humans
Incidence
Infusion Pumps
Injections, Epidural
Lidocaine
Morphine*
Pregnancy
Visual Analog Scale
Bupivacaine
Fentanyl
Lidocaine
Morphine
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr